Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
dc.contributor.author | Sheikh, Hamid Y | |
dc.contributor.author | Valle, Juan W | |
dc.contributor.author | Palmer, Karen | |
dc.contributor.author | Sjursen, Ann-Marie | |
dc.contributor.author | Craven, Olive | |
dc.contributor.author | Wilson, Gregory | |
dc.contributor.author | Swindell, Ric | |
dc.contributor.author | Saunders, Mark P | |
dc.date.accessioned | 2009-06-30T12:23:08Z | |
dc.date.available | 2009-06-30T12:23:08Z | |
dc.date.issued | 2007-01-15 | |
dc.identifier.citation | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. 2007, 96 (1):38-43 Br. J. Cancer | en |
dc.identifier.issn | 0007-0920 | |
dc.identifier.pmid | 17213824 | |
dc.identifier.doi | 10.1038/sj.bjc.6603521 | |
dc.identifier.uri | http://hdl.handle.net/10541/71937 | |
dc.description.abstract | The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mg m(-2) on day 1, oxaliplatin 85-100 mg m(-2) on day 15 and UFT 200-300 mg m(-2) day(-1) with LV 90 mg day(-1), days 1-21 of a 28-day cycle. Patients were treated in cohorts of three. At the highest dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 300 mg m(-2) day(-1)), three of four patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2 toxicities at the maximum tolerated dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 250 mg m(-2) day(-1)). There were no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for patients with advanced colorectal cancer. We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies. | |
dc.language.iso | en | en |
dc.subject | Colorectal Cancer | en |
dc.subject.mesh | Administration, Oral | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Camptothecin | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | Disease Progression | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Drug Administration Schedule | |
dc.subject.mesh | Drug Combinations | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Infusions, Intravenous | |
dc.subject.mesh | Leucovorin | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Organoplatinum Compounds | |
dc.subject.mesh | Survival Rate | |
dc.subject.mesh | Tegafur | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Uracil | |
dc.title | Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study. | en |
dc.type | Article | en |
dc.contributor.department | Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. | en |
dc.identifier.journal | British Journal of Cancer | en |
html.description.abstract | The feasibility of combining UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin was investigated in the first-line treatment of patients with advanced colorectal cancer. Twenty-five patients, median age 63 (range 24-79) years, World Health Organisation performance status 0-2 and median four marker lesions, received irinotecan 180 mg m(-2) on day 1, oxaliplatin 85-100 mg m(-2) on day 15 and UFT 200-300 mg m(-2) day(-1) with LV 90 mg day(-1), days 1-21 of a 28-day cycle. Patients were treated in cohorts of three. At the highest dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 300 mg m(-2) day(-1)), three of four patients experienced grade 3 toxicity. Diarrhoea, lethargy and vomiting were dose-limiting. Three of nine patients had grade 2 toxicities at the maximum tolerated dose (irinotecan 180 mg m(-2), oxaliplatin 100 mg m(-2) and UFT 250 mg m(-2) day(-1)). There were no grade 3 toxicities in the first month of therapy. The overall response rate was 71% in 21 evaluable patients; progression-free survival was 8.8 months. Alternating irinotecan and oxaliplatin plus UFT is an effective and well-tolerated first-line treatment for patients with advanced colorectal cancer. We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies. |